GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » Net Income Including Noncontrolling Interests

Roche Holding AG (Roche Holding AG) Net Income Including Noncontrolling Interests : $13,944 Mil (TTM As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Roche Holding AG Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Roche Holding AG's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was $5,545 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was $13,944 Mil.


Roche Holding AG Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Roche Holding AG's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Net Income Including Noncontrolling Interests Chart

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14,357.83 16,960.83 16,216.07 14,524.47 14,290.01

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,295.33 9,442.38 4,690.85 8,399.60 5,544.63

Roche Holding AG Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $13,944 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (Roche Holding AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » Net Income Including Noncontrolling Interests
Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (Roche Holding AG) Headlines

From GuruFocus

Analysts Tab Veeva Systems as a Top Value Pick

By Barry Cohen 05-25-2022

Roche expands long-term alliance with Sysmex

By PRNewswire 08-03-2023